NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Reliability of Rimegepant or Triptans for the Acute Treatment of Migraine

CompletedN/A

Sponsor: Pfizer

Conditions: Migraine Disorders

Countries: United States

This protocol describes the analysis of the Adelphi Real World (ARW) Migraine Disease Specific Programme(TM) 2022, a cross-sectional study which used both physician and patient surveys to assess the perception of the acute treatment for migraine attacks.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion criteria

* Patients who have episodic and/or chronic migraine
* Patients age \> 18
* Currently prescribed rimegepant OR triptans for the acute treatment of migraine

Exclusion criteria

* currently prescribed rimegepant for prevention of migraine or for both the acute treatment \& prevention of migraine
* Rimegepant group: currently prescribed an acute treatment for migraine and other than rimegepant
* Triptan Group: currently prescribed an acute treatment for migraine other than triptans

Locations (1)

New York, New York, United States